Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs

Reuters

Mar 06

Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs

Overview

Oncology company's Q4 loss per share beat analyst expectations
Net loss for Q4 beat analyst estimates
Company ended 2025 with $217 mln in cash, funding operations into 2029

Result Drivers

LOWER RESEARCH AND DEVELOPMENT (R&D) EXPENSES: R&D expenses for the fourth quarter of 2025 were $9.3 million compared to $14.9 million for the fourth quarter of 2024.
CASH POSITION - Ended 2025 with $217 mln in cash, ensuring funding into 2029

Company press release: ID:nGNX2KvBt6

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 EPS	Beat	-$0.18	-$0.31 (6 Analysts)
Q4 Net Income	Beat	-$11.60 mln	-$20.81 mln (4 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immuneering Corp is $14.00, about 181.1% above its March 5 closing price of $4.98

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2617680155"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617680155\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617680155?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617680155","market":"nz","top_or_hot":-1,"title":"Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Immuneering posts smaller‑than‑expected Q4 loss on reduced R&amp;D costs</title></head><body><p><span>Overview</span></p><ul><li><p>Oncology company's Q4 loss per share beat analyst expectations</p></li><li><p>Net loss for Q4 beat analyst estimates</p></li><li><p>Company ended 2025 with $217 mln in cash, funding operations into 2029</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER RESEARCH AND DEVELOPMENT (R&amp;D) EXPENSES: R&amp;D expenses for the fourth quarter of 2025 were $9.3 million compared to $14.9 million for the fourth quarter of 2024. </p></li><li><p>CASH POSITION - Ended 2025 with $217 mln in cash, ensuring funding into 2029</p></li></ul><p>Company press release: <span>ID:nGNX2KvBt6</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td><p>Beat</p></td><td><p>-$0.18</p></td><td><p>-$0.31 (6 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td><p>Beat</p></td><td><p>-$11.60 mln</p></td><td><p>-$20.81 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/IMRX\">Immuneering Corp</a> is $14.00, about 181.1% above its March 5 closing price of $4.98</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneering posts smaller‑than‑expected Q4 loss on reduced R&D costs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-06 20:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Immuneering posts smaller‑than‑expected Q4 loss on reduced R&amp;D costs</title></head><body><p><span>Overview</span></p><ul><li><p>Oncology company's Q4 loss per share beat analyst expectations</p></li><li><p>Net loss for Q4 beat analyst estimates</p></li><li><p>Company ended 2025 with $217 mln in cash, funding operations into 2029</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>LOWER RESEARCH AND DEVELOPMENT (R&amp;D) EXPENSES: R&amp;D expenses for the fourth quarter of 2025 were $9.3 million compared to $14.9 million for the fourth quarter of 2024. </p></li><li><p>CASH POSITION - Ended 2025 with $217 mln in cash, ensuring funding into 2029</p></li></ul><p>Company press release: <span>ID:nGNX2KvBt6</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 EPS</p></td><td><p>Beat</p></td><td><p>-$0.18</p></td><td><p>-$0.31 (6 Analysts)</p></td></tr><tr><td><p>Q4 Net Income</p></td><td><p>Beat</p></td><td><p>-$11.60 mln</p></td><td><p>-$20.81 mln (4 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for <a href=\"https://laohu8.com/S/IMRX\">Immuneering Corp</a> is $14.00, about 181.1% above its March 5 closing price of $4.98</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL1N3ZU0JR:1","article_id":"2617680155","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617680155","pubTimestamp":1772801774,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immuneering posts smallerthanexpected Q4 loss on reduced R&D costsOverviewOncology company's Q4 loss per share beat analyst expectationsNet loss for Q4 beat analyst estimatesCompany ended 2025 with $2","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","IMRX":"Immuneering Corp","BK4139":"生物科技","BK4539":"次新股"},"translate_title":"由于研发成本降低，Immuneering第四季度亏损小于预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMRX":0.9},"content_text":"Immuneering posts smaller‑than‑expected Q4 loss on reduced R&D costsOverviewOncology company's Q4 loss per share beat analyst expectationsNet loss for Q4 beat analyst estimatesCompany ended 2025 with $217 mln in cash, funding operations into 2029Result DriversLOWER RESEARCH AND DEVELOPMENT (R&D) EXPENSES: R&D expenses for the fourth quarter of 2025 were $9.3 million compared to $14.9 million for the fourth quarter of 2024. CASH POSITION - Ended 2025 with $217 mln in cash, ensuring funding into 2029Company press release: ID:nGNX2KvBt6Key DetailsMetricBeat/MissActualConsensus EstimateQ4 EPSBeat-$0.18-$0.31 (6 Analysts)Q4 Net IncomeBeat-$11.60 mln-$20.81 mln (4 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Immuneering Corp is $14.00, about 181.1% above its March 5 closing price of $4.98For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}